questionsmedicales.fr
Maladies de la peau et du tissu conjonctif
Maladies de la peau
Sclérodermie systémique
Sclérodermie diffuse
Sclérodermie diffuse : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Sclérodermie
Diagnostic médical
Signes cliniques
Sclérodermie
Radiographie
Sclérodermie
Symptômes
5
Symptômes respiratoires
Sclérodermie
Atteinte digestive
Sclérodermie
Troubles vasculaires
Sclérodermie
Prévention
5
Facteurs de risque
Sclérodermie
Exposition au froid
Sclérodermie
Traitements
5
Corticostéroïdes
Sclérodermie
Kinésithérapie
Sclérodermie
Traitements expérimentaux
Sclérodermie
Symptômes cutanés
Sclérodermie
Complications
5
Complications
Sclérodermie
Atteintes cardiaques
Sclérodermie
Atteintes rénales
Sclérodermie
Complications digestives
Sclérodermie
Facteurs de risque
5
Facteurs de risque
Sclérodermie
Facteurs environnementaux
Sclérodermie
Maladies auto-immunes
Sclérodermie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Sclérodermie diffuse : Questions médicales les plus fréquentes",
"headline": "Sclérodermie diffuse : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Sclérodermie diffuse : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-29",
"dateModified": "2025-02-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Sclérodermie systémique",
"url": "https://questionsmedicales.fr/mesh/D012595",
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie systémique",
"code": {
"@type": "MedicalCode",
"code": "D012595",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C17.800.784"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Sclérodermie diffuse",
"alternateName": "Scleroderma, Diffuse",
"code": {
"@type": "MedicalCode",
"code": "D045743",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Dinesh Khanna",
"url": "https://questionsmedicales.fr/author/Dinesh%20Khanna",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA."
}
},
{
"@type": "Person",
"name": "Christopher P Denton",
"url": "https://questionsmedicales.fr/author/Christopher%20P%20Denton",
"affiliation": {
"@type": "Organization",
"name": "UCL Division of Medicine, Royal Free Campus, London, UK."
}
},
{
"@type": "Person",
"name": "Ami A Shah",
"url": "https://questionsmedicales.fr/author/Ami%20A%20Shah",
"affiliation": {
"@type": "Organization",
"name": "Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu."
}
},
{
"@type": "Person",
"name": "Susanna Proudman",
"url": "https://questionsmedicales.fr/author/Susanna%20Proudman",
"affiliation": {
"@type": "Organization",
"name": "Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Medication error with methotrexate.",
"datePublished": "2024-03-21",
"url": "https://questionsmedicales.fr/article/38747669",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4045/tidsskr.23.0657"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Detection of anticoagulant medication errors by triggers].",
"datePublished": "2024-09-14",
"url": "https://questionsmedicales.fr/article/39404718",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.26442/00403660.2024.08.202817"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reducing Medication Errors in Children's Hospitals.",
"datePublished": "2023-01-14",
"url": "https://questionsmedicales.fr/article/36728168",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/PTS.0000000000001087"
}
},
{
"@type": "ScholarlyArticle",
"name": "Medication reconciliation in pediatrics: a validation of instruments to prevent medication errors.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36888795",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1590/0034-7167-2021-0755"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of raltegravir formulation change on medication adherence and medication errors.",
"datePublished": "2022-08-25",
"url": "https://questionsmedicales.fr/article/36002310",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5582/ddt.2022.01054"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de la peau et du tissu conjonctif",
"item": "https://questionsmedicales.fr/mesh/D017437"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de la peau",
"item": "https://questionsmedicales.fr/mesh/D012871"
},
{
"@type": "ListItem",
"position": 4,
"name": "Sclérodermie systémique",
"item": "https://questionsmedicales.fr/mesh/D012595"
},
{
"@type": "ListItem",
"position": 5,
"name": "Sclérodermie diffuse",
"item": "https://questionsmedicales.fr/mesh/D045743"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Sclérodermie diffuse - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Sclérodermie diffuse",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Sclérodermie diffuse",
"description": "Comment diagnostiquer la sclérodermie diffuse ?\nQuels tests sanguins sont utilisés ?\nLes biopsies cutanées sont-elles nécessaires ?\nQuels signes cliniques sont observés ?\nLa radiographie est-elle utile dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Sclérodermie diffuse",
"description": "Quels sont les symptômes principaux ?\nLa fatigue est-elle un symptôme courant ?\nY a-t-il des symptômes respiratoires ?\nComment se manifeste l'atteinte digestive ?\nLes troubles vasculaires sont-ils fréquents ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Sclérodermie diffuse",
"description": "Peut-on prévenir la sclérodermie diffuse ?\nQuels facteurs de risque sont identifiés ?\nLe tabagisme influence-t-il la maladie ?\nL'exposition au froid est-elle un risque ?\nLes infections peuvent-elles aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Sclérodermie diffuse",
"description": "Quels traitements sont disponibles ?\nLes corticostéroïdes sont-ils efficaces ?\nQuelles thérapies physiques sont recommandées ?\nY a-t-il des traitements expérimentaux ?\nComment gérer les symptômes cutanés ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Sclérodermie diffuse",
"description": "Quelles sont les complications possibles ?\nLa sclérodermie peut-elle affecter le cœur ?\nY a-t-il un risque d'infections ?\nComment la sclérodermie affecte-t-elle les reins ?\nLes complications digestives sont-elles fréquentes ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Sclérodermie diffuse",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils significatifs ?\nY a-t-il un lien avec d'autres maladies auto-immunes ?\nLe stress peut-il aggraver la maladie ?",
"url": "https://questionsmedicales.fr/mesh/D045743?mesh_terms=Medication+Errors#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer la sclérodermie diffuse ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'examen clinique, les antécédents médicaux et des tests sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent la recherche d'anticorps spécifiques comme les anticorps anti-Scl-70."
}
},
{
"@type": "Question",
"name": "Les biopsies cutanées sont-elles nécessaires ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent être réalisées pour évaluer l'atteinte tissulaire et confirmer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont observés ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent un durcissement de la peau, des œdèmes et des troubles vasculaires."
}
},
{
"@type": "Question",
"name": "La radiographie est-elle utile dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer les atteintes pulmonaires ou digestives associées."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes principaux ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent un durcissement de la peau, des douleurs articulaires et des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue est fréquente et peut être liée à l'inflammation et à l'atteinte organique."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes respiratoires ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des difficultés respiratoires peuvent survenir en raison de l'atteinte pulmonaire."
}
},
{
"@type": "Question",
"name": "Comment se manifeste l'atteinte digestive ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se traduire par des reflux, des troubles de la déglutition et des douleurs abdominales."
}
},
{
"@type": "Question",
"name": "Les troubles vasculaires sont-ils fréquents ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des phénomènes de Raynaud et des ulcères digitaux peuvent se produire."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir la sclérodermie diffuse ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention connue, mais éviter les facteurs de risque peut aider."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont identifiés ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des expositions environnementales et le sexe féminin."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la maladie ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut aggraver les symptômes et augmenter le risque de complications."
}
},
{
"@type": "Question",
"name": "L'exposition au froid est-elle un risque ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition au froid peut déclencher des symptômes vasculaires comme le phénomène de Raynaud."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles aggraver la maladie ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent exacerber les symptômes et compliquer la gestion de la maladie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunosuppresseurs, des anti-inflammatoires et des thérapies symptomatiques."
}
},
{
"@type": "Question",
"name": "Les corticostéroïdes sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent réduire l'inflammation, mais leur utilisation doit être prudente en raison des effets secondaires."
}
},
{
"@type": "Question",
"name": "Quelles thérapies physiques sont recommandées ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La kinésithérapie peut aider à maintenir la mobilité et à réduire la douleur articulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des traitements comme les inhibiteurs de la tyrosine kinase sont en cours d'évaluation."
}
},
{
"@type": "Question",
"name": "Comment gérer les symptômes cutanés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des crèmes hydratantes et des traitements topiques peuvent aider à soulager les symptômes cutanés."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des atteintes pulmonaires, cardiaques et rénales, ainsi que des troubles digestifs."
}
},
{
"@type": "Question",
"name": "La sclérodermie peut-elle affecter le cœur ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut entraîner des arythmies, une hypertension pulmonaire et une insuffisance cardiaque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque d'infections ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les patients peuvent être plus susceptibles aux infections en raison d'une immunité altérée."
}
},
{
"@type": "Question",
"name": "Comment la sclérodermie affecte-t-elle les reins ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut provoquer une hypertension rénale et une insuffisance rénale, nécessitant une surveillance."
}
},
{
"@type": "Question",
"name": "Les complications digestives sont-elles fréquentes ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles incluent des reflux, des troubles de la motilité et des malabsorption."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents familiaux, le sexe féminin et certaines expositions environnementales sont des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'âge joue-t-il un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la sclérodermie diffuse survient généralement entre 30 et 50 ans, mais peut toucher d'autres âges."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des solvants organiques et à la silice peut augmenter le risque."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec d'autres maladies auto-immunes ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes ayant d'autres maladies auto-immunes peuvent avoir un risque accru."
}
},
{
"@type": "Question",
"name": "Le stress peut-il aggraver la maladie ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut exacerber les symptômes, bien que son rôle exact dans la sclérodermie ne soit pas clair."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 23/02/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
4 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Publications dans "Sclérodermie diffuse" :
4 publications dans cette catégorie
Affiliations :
UCL Division of Medicine, Royal Free Campus, London, UK.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA. Electronic address: Ami.Shah@jhmi.edu.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy. francescozulian58@gmail.com.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Georgetown University Medical Center, Washington (DC), USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Lady Davis Institute of the Jewish General Hospital, 4333 Côte-Sainte-Catherine Road,, Montréal, Québec, H3T 1E4, Canada. brett.thombs@mcgill.ca.
Department of Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Psychiatry, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Medicine, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Educational and Counselling Psychology, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Department of Biomedical Ethics Unit, McGill University, Montreal, Canada. brett.thombs@mcgill.ca.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Publications dans "Sclérodermie diffuse" :
3 publications dans cette catégorie
Affiliations :
University of Pittsburgh, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland.
Departament of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Lodz, Poland.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine and Rheumatology, Justus-Liebig University Giessen, Giessen, Germany.
Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Bad Nauheim, Germany.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Division of Rheumatology, Johns Hopkins University School of Medicine, 5200 Eastern Avenue, Mason F. Lord Building, Center Tower, Suite 4100, Baltimore, MD 21224, USA.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Rheumatology Unit, Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
Publications dans "Sclérodermie diffuse" :
2 publications dans cette catégorie
Affiliations :
Department of Woman's and Child's Health, University of Padua, Via Giustiniani 3, 35128, Padua, Italy.
Publications dans "Sclérodermie diffuse" :
A woman in her seventies presented to the accident and emergency department (A&E) with shortness of breath that had increased over a period of three weeks. She had a history of COPD, hypertension and ...
The patient arrived with stable vital signs, including 94 % oxygen saturation and a respiratory rate of 20 breaths/min. She had been taking 2.5 mg of methotrexate daily for the past three weeks instea...
Considering her medical history and exclusion of other differential diagnoses, methotrexate toxicity was suspected. The patient was admitted to the hospital and intravenous folinic acid was initiated ...
Medication errors can cause preventable adverse events. For example, inappropriate use of anticoagulants (AC) can result in bleeding and thromboembolic complications. Detection and analysis of AC medi...
The study was aimed to develop a method of systematic detection of anticoagulant medication errors for consequent audit, analysis and development of medication safety improvement measures....
The study was conducted in the multidisciplinary hospital and included 4924 patients admitted from January 2019 to December 2021 who received AC. Three laboratory triggers (international normalized ra...
Of the 4924 patients 253 (5.3%) were selected by combined triggers. Combined trigger allowed to reduce the amount of medical health records audit by 97.3%. Medication errors were detected in 137 patie...
Method of systematic detection of AC medication errors using combined triggers in all hospitalized patients receiving AC allowed to reveal typical medication errors for consequent analysis and elabora...
Knowledge of the prevalence and characteristics of medication errors in pediatric and neonatal patients is limited. This study aimed to evaluate the incidence and medication error characteristics in a...
We retrospectively reviewed medication errors documented between January 2015 and December 2019....
A total of 2,591,596 prescriptions were checked, and 255 errors were identified. Wrong dose prescriptions constituted the most common errors (56.9%). Medications with the highest rate of errors were a...
The incidence of medication errors decreased with extensive use of the CPOE system. Continuous application of the CPOE optimization program can effectively reduce medication errors. Further incorporat...
to develop and validate the content of two instruments for promoting medication reconciliation for the transition of care of hospitalized children....
methodological study, conducted in five stages: scope review for conceptual structure; elaboration of the initial version; content validation with five specialists using the Delphi technique; reassess...
three rounds of evaluation were carried out to reach the validity index of the proposed contents, whereas a new analysis of 50% of the 20 items of the instrument aimed at families, and 28.5% of the 21...
the proposed instruments were validated. It is now possible to proceed with practical implementation studies to identify their influence on safety during medication reconciliation at transition of car...
This study was aimed at assessing the adherence and incorrect drug intake associated with changes in the dosing schedule of raltegravir, the first integrase strand transfer inhibitor, from 400 mg twic...
Accuracy is needed with medication administration, a skill that involves rule-based habits and clinical reasoning. This pilot study investigated the use of an evidence-based checklist for accuracy wit...
Nineteen participants randomly assigned to crossover sequence AB or BA (A: checklist; B: no checklist) practiced simulation scenarios with embedded errors. Nursing faculty used an observation form to ...
Using the C-MATCH-REASON...
C-MATCH-REASON© was effective for error reduction. Study replication with a larger sample is warranted....
The administration of intravenous (IV) medications is a technically complicated and error-prone process. Especially, in the hematopoietic stem cell transplantation (HSCT) setting where toxic drugs are...
This was an observational, cross-sectional study. A total of 525 episodes of IV medication administration were reviewed by a pharmacist using the disguised direct observation method to evaluate the pr...
A total of 1,568 errors were observed out of 5,347 total potential errors. TOE was calculated as 2.98 or 298% and CTOE as 29.3%. Most of the errors occurred at the administration step. The most common...
Medication errors frequently occur during the preparation and administration of IV medications in the HSCT setting. Using precise detection methods, denominators, and checklists, we identified the mos...
Paediatric patients are prone to medication errors, and only a few studies have explored errors in high-alert medications in children. The present study aimed to investigate the prevalence and nature ...
This study was a cross-sectional report of self-reported medication errors in a paediatric university hospital in 2018-2020. Medication error reports involving high-alert medications were investigated...
Among the reported errors (n = 2,132), approximately one-third (34.8%, n = 743) involved high-alert medications (n = 872). The most common Anatomical Therapeutic Chemical subgroups were blood substitu...
Preventive risk management should be targeted on high-alert medications in paediatric hospital settings. In these actions, the use of intravenous drugs, such as parenteral nutrition, concentrated elec...
Medication error is a common cause of patient harm. The study aims to propose a way to manage the risk of medication errors in a novel way, by identifying practice areas where mitigating patient harm ...
Suspected Adverse Drug Reactions (sADRs) in Eudravigilance database over three years were reviewed to identify preventable medication errors. These were classified using a new method based upon the ro...
Overall, 2294 medication errors were identified from Eudravigilance, of which 1300 (57%) were due to pharmacotherapeutic failure. Most cases of preventable medication error involved prescribing (41%) ...
The findings of this study highlight the feasibility of using a novel conceptual framework to identify areas of practice at risk of pharmacotherapeutic failure where Interventions by healthcare profes...
Medication errors (MEs) in hospitals decrease patient satisfaction, increase hospital mortality, lower hospital productivity, and increase in the costs of the health system. This study was conducted t...
In this meta-analysis, all published articles on ME rates in Iranian hospitals were identified from five databases and Google Scholar and assessed for quality. The heterogeneity of the studies was exa...
Based on the estimation of the random-effects model, the ME rate in Iranian hospitals was 10.9% (5.1%-21.7%; 95% CI). The highest rate was observed in Sanandaj in 2006 at 99.5% (92.6%-100.0%; 95% CI) ...
According to the results of this study; ME rate in Iran is relatvively high based on the synthesis of the research conducted in Iranian hospitals. In addition to being costly, MEs have negative conseq...